Navigation Links
Denosumab reduces burden of giant-cell tumor of the bone
Date:9/21/2012

PHILADELPHIA Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"Giant-cell tumor of the bone is a rare tumor that affects mostly young people," said Sant P. Chawla, M.D., director of the Santa Monica Oncology Center, Santa Monica, Calif. "Radical surgery is currently the only treatment option. In our study, the use of denosumab allowed patients to avoid radical surgery and prevented recurrence. We hope that in the future, its use may make it possible to avoid surgery completely."

Giant-cell tumor of the bone is a benign tumor characterized by giant cells that are positive for the protein RANK ligand, which helps promote bone destruction. Currently, the only treatment option for patients with giant-cell tumor of the bone is surgery. However, patients who undergo surgery often have recurrent disease or significant morbidity, such as amputation. In addition, 25 to 30 percent of patients with this tumor have to undergo joint replacements.

Chawla and colleagues conducted this phase II study to explore the mechanism of action of denosumab, an inhibitor of RANK ligand, in the treatment of giant-cell tumor of the bone.

Twenty adult patients with recurrent or unresectable giant-cell tumor of the bone were treated with subcutaneous denosumab every four weeks. After treatment, all 20 of the patients had a decrease in giant cells of 90 percent or greater, an indicator of a reduction of tumor burden. In addition, results indicated that 65 percent of the patients had new bone growth in areas where the RANK ligand had previously caused bone destruction.

"A majority of patients with giant-cell tumor of the bone are young and have to get joint replacements, which last 15 to 20 years before a repeat surgery is needed," Chawla said. "Now, we hopefully can do minimal surgery, avoiding a joint replacement and recurrence."

One of the next steps in evaluating denosumab for giant-cell tumor of the bone is a much larger, multinational study that is currently enrolling patients. In addition, Chawla hopes to evaluate the use of denosumab as a presurgery, or neoadjuvant, treatment as well.

"In the future we hope to investigate giving the drug prior to surgery to see the effect it has, then remove the tumor and evaluate the pathological response," Chawla said.

This study was funded by Amgen.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
2. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
3. Automated breast ultrasound dramatically reduces physician interpretation time
4. NIH study finds sigmoidoscopy reduces colorectal cancer rates
5. Surgical removal of abdominal fat reduces skin cancer in mice
6. Long-term ICS use reduces pleural effusion in patients with CAP
7. Regional anesthesia reduces complications and death for hip fracture patients
8. Surgical sling reduces risk of weakened bladder control after prolapse surgery, U-M study says
9. Single embryo transfer reduces the risk of perinatal mortality in IVF
10. HPV vaccine reduces infection, even in unvaccinated
11. HIV drug reduces graft-vs.-host disease in bone marrow transplant patients, Penn study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Orleans, LA (PRWEB) , ... December 07, 2016 ... ... technique used to treat wrinkles and deep lines by smoothing and tightening the ... minimally invasive techniques out there to address facial aging with very little downtime, ...
(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... to blow out his candles on his 14th birthday, Estefano Reano had only one wish: ... Joe DiMaggio Children’s Hospital surprised his family with a phone call that made his wish ... was playing at home, when we got the phone call telling us there was a ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, ... is painful for her. "This is why the co-inventor and I have designed a ... They then created a prototype of the patent-pending AV-AIR, a device that serves as ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. ... income of $18,800,000, or $0.45 per diluted share, on a ... first quarter ended October 31, 2016. This compares with net ... of $153,779,000 for the first quarter ended October 31, 2015. ... first quarter ended October 31, 2016 to $21,323,000, or $0.51 ...
(Date:12/8/2016)... , Dec. 8, 2016   Mederi Therapeutics Inc . has announced regulatory ... Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). ... ... and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director ... , , "We are very ...
(Date:12/8/2016)... BEIJING , and SAN DIEGO , ... genomic services and solutions with cutting edge next-generation sequencing and ... biotechnology company; and the Genome Institute of ... (NovogeneAIT) – a new joint venture between Novogene and AITbiotech ... at Biopolis, Singapore .   ...
Breaking Medicine Technology: